Juno Therapeutics
NEWS
Juno Therapeutics was acquired by Bristol-Myers Squibb in 2019.
STAT reflected back on this year and felt one company stood out for rebounding from tough times.
Juno Therapeutics is now the “cheapest” player now developing CAR-T cancer medications, an analyst said Wednesday as he downgraded rival Bluebird Bio.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
CAR-T is a hot new area and there are companies hot on Gilead’s tail, namely Juno, in a partnership with Celgene, and Novartis.
Neurotoxicity killed JCAR015 right along with 5 patients in the lead pivotal study, derailing Juno Therapeutics.
Noting that biotech stocks have been in “hypergrowth” mode over more than six years, George Budwell, writing for The Motley Fool, looks at three biotech stocks that he would recommend to investors.
JOBS
IN THE PRESS